Comparative Pharmacology
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus XYZAL ALLERGY 24HR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRIPROLIDINE AND PSEUDOEPHEDRINE versus XYZAL ALLERGY 24HR.
TRIPROLIDINE AND PSEUDOEPHEDRINE vs XYZAL ALLERGY 24HR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Triprolidine is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing histamine-mediated allergic symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the respiratory tract mucosa, causing vasoconstriction and decreased nasal congestion.
Levocetirizine is the active R-enantiomer of cetirizine, a second-generation antihistamine. It selectively inhibits peripheral H1 receptors, reducing histamine-mediated allergic responses such as itching, sneezing, and rhinorrhea.
1 tablet (2.5 mg triprolidine/60 mg pseudoephedrine) orally every 4-6 hours; max 4 tablets/24 hours.
5 mg (1 tablet) orally once daily, preferably in the evening.
None Documented
None Documented
Triprolidine: 2-4 hours (parent compound). Pseudoephedrine: 4-8 hours, prolonged in alkaline urine (up to 16-24 hours).
Terminal elimination half-life is approximately 8-9 hours in healthy adults. In patients with renal impairment (CrCl <30 mL/min), half-life may be prolonged to up to 21 hours.
Triprolidine: renal, 70% unchanged and metabolites. Pseudoephedrine: renal, 90% unchanged.
Primarily renal excretion; approximately 85% of the dose is excreted unchanged in urine, with the remainder as metabolites (mainly the conjugate) in feces via biliary elimination (~10-13%).
Category A/B
Category C
Antihistamine
Antihistamine